The Food and Drug Administration
is expected to issue a new warning about the increased risk of Guillain-Barré syndrome, a rare neurological disorder, to the Johnson & Johnson COVID-19 vaccine
According to The New York Times
, regulators stated that the risk of recipients developing
the autoimmune disorder that affects the nerves was low and that the benefits of receiving the COVID-19 vaccine outweighed the risk.
According to the Centers for Disease Control and Prevention
, approximately 100 cases of Guillain-Barré syndrome have been reported out of nearly 13 million people
in the United States
who received the one-dose Johnson & Johnson vaccine. Cases have been reported primarily in men over the age of 50 and began about two weeks after vaccination, according to The Washington Post
According to the Centers for Disease Control and Prevention, most people recover completely from Guillain-Barré syndrome.
The Johnson & Johnson vaccine is still 85% effective at preventing severe disease and 100% effective at preventing hospitalization and death
, which are the primary goals of COVID-19 vaccination.
“The risk of severe adverse events following COVID-19 vaccination remains rare,” the CDC
said in a statement
, adding that “everyone aged 12 and older is recommended to receive a COVID-19 vaccine.”
Earlier this year, the Johnson & Johnson vaccine rollout was temporarily halted due to concerns about extremely rare blood clots in some recipients.
Currently, over 184 million people in the United States have received at least one dose of a COVID-19 vaccine, including the Pfizer
and Moderna vaccines
, which require two doses.
cases and deaths have decreased dramatically in the United States since vaccinations
became widely available in the spring, and the vast majority of cases now occur in people who have not been vaccinated.